Ind-Swift Laboratories Ltd.

INDSWFTLAB

₹85.8

1.31% (1.11)

Market Cap

₹522 Cr.

P/E

2.17

About

Ind-Swift Laboratories Ltd, a public limited company established in 1995, is a global manufacturer of APIs, Intermediates, and formulations. Specializing in API manufacturing since 1997, the company i… Read more

Ind-Swift Laboratories Ltd, a public limited company established in 1995, is a global manufact… Read more

Low

52W Range

High

186

Timeline

Key company specific updates

Company Timeline

Subscribe now for more updates

Custom financial statementNew

Edit rows

Forensics

8 Yes

Positive for this company

2 Neutral

Neutral for this company

6 No

Negative for this company

1 No Data

Insufficient data to analyse

Accounting & Shareholding

Contingent Liabilities

Company does not have significant contingent liabilities
Other Income

Other income is not affecting ratios of the company
Pledge

Promoters have not pledged a significant portion of their holding
Revenue Recognition

Company is converting accounting profit to cash
Promoter Holding

Promoter has not sold any shares in the last 90 days
Depreciation Effect

Company is depreciating a lower percentage of assets. this is contributing to an increase in net profit
Retail Holding

Retail has been buying the stock which is usually a sign of exuberance

Price & Performance

Capex vs ROCE

Roce of the company has increased over the last three years
ROE

Net profit margin is responsible for roe increase over last 10 years
Working Capital

Working capital of the company seems to be under control
Debt

Company should not have issues servicing its debt
Balance Sheet Strength

Balance sheet of the company is strong. but it might have issues paying it suppliers
Share price

Share price has increased over last 10 years but more due to rerating
Sales Growth

Sales of the company has grown at a slow pace
Margin Stability

Margins of the company are volatile
ROCE Strength

Roce of the company is not consistently strong
Current vs Historic Valuation

Unable to calculate due to limited data

Market Share

10 %

(as of Mar 20)

Source/Historic

Atorvastatin (Digestive) - Market Share

25 %

(as of Mar 20)

Source/Historic

Clarithromycin (Respiratory) - Market Share

15 %

(as of Mar 20)

Source/Historic

Clopidogrel (Cardio) - Market Share

8 %

(as of Mar 20)

Source/Historic

Ezetimibe (Cardio) - Market Share

20 %

(as of Mar 20)

Source/Historic

Fexofenadine (Anti-Allergic) - Market Share

25 %

(as of Mar 20)

Source/Historic

Ivabradine (Cardio) - Market Share

40 %

(as of Mar 20)

Source/Historic

Nitazoxanide (Digestive) - Market Share

Revenue mix

Product Wise Break-Up

Location Wise Break-Up

Operating Profit Break-Up

Asset Break-Up

Operational Metrics

Total reactor capacity (kL)
Source
DMF Filingsby API (.)
R&D as a % of Total Sales (%)
Source

Peer Comparison

FAQs on Ind-Swift Laboratories Ltd. Business

What does Ind-Swift Lab. do?

Ind-Swift Laboratories Ltd, based in Chandigarh, India, is a global manufacturer of APIs, Intermediates, and formulations. Established in 1995, the company focuses on API manufacturing and is a key player in the Indian pharmaceutical industry.

Who are the competitors of Ind-Swift Lab.?

Ind-Swift Lab. major competitors are Albert David, Medico Remedies, Jenburkt Pharma, Kilitch Drugs(India), Venus Remedies, Zim Laboratories, Medicamen Biotech.
Market Cap of Ind-Swift Lab. is ₹515 Crs.
While the median market cap of its peers are ₹481 Crs.

Is Ind-Swift Lab. financially stable compared to its competitors?

Ind-Swift Lab. seems to be less financially stable compared to its competitors.
Altman Z score of Ind-Swift Lab. is 4.65 and is ranked 5 out of its 8 competitors.

View FAQ's On Shareprice

Global Leaders

Companies with a dominant global position in a product. Might be a sign of very strong moat.

Run Query

Companies Doing Major Expansion

Companies in any sector undergoing sizeable expansion

Run Query

Company Filing

	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010
Annual Report	FY25	FY24	FY23	FY22	FY21	FY20	FY19	FY18	FY17	FY16	FY15	FY14	FY13	FY12	FY11	FY10
Earnings Release			Mar
Investor Presentation						Jun Sep
Conference Call
Conference Call SummaryCon Call Summary Powered by Gemini

Discussions & Analysis

Pharmaceutical Sector

How The Pharma Industry Works - PPFAS

Deep Dive into Pharma Sector - Omkara Capital

Pharma Compliance In-Depth - Amit Rajan

Nutraceuticals - The Next Gem of Healthcare Sector - Shuchi Nahar

Nutraceuticals- Industry Overview - Value Educator

Generic Opportunity for Indian Pharma Companies - Anish Moonka

Understanding the CDMO Sector - Will It Be The Next Megatrend - SOIC

Ideas Dashboard

Timeline

Watchlist

Portfolio

Alerts

Research

Stock Screener

Market

Raw Material

Ind-Swift Laboratories Ltd.